Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

Completed · Phase 3

Conditions studied: Hypertension

In brief

The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).

Key facts

Study ID

NCT00350168

Run by

Novartis

People needed

647

Starts

2006-06-01

Expected to finish

2007-04-01

Last updated by the study team

2016-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older.
• Moderate to severe high blood pressure. This is defined as a systolic pressure (the top number) greater than or equal to 160 mmHg and less than 200 mmHg.

You may not qualify if…

• History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics
• Inability to stop all prior blood pressure medications safely
• Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg
• Controlled blood pressure (systolic BP < 140 mmHg) taking more than 3 antihypertensive medications at screening
• Systolic BP ≥ 140 mmHg and < 180 mmHg taking more than two antihypertensive medications at screening
• Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening
• History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or unstable angina
• Type 1 diabetes
• Poorly controlled Type 2 diabetes
• History of heart failure
• Arrhythmia
• Significant valvular heart disease
• Active gout
• History of autoimmune diseases
• History of multiple drug allergies
• Liver disease
• Pancreatic injury within 1 year of screening
• Evidence of kidney impairment or history of dialysis
• Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of any drug. This could include currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.
• Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically sterile OR are using acceptable methods of contraception. The use of hormonal contraceptives is not allowed
• Pregnant or nursing (lactating) women
• History of malignancy of any organ system within the past five years
• Any severe, life-threatening disease within the past five years
• History of drug or alcohol abuse within the last 2 years.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Pharmaceuticals Corp — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.